VYNE Therapeutics completes 1:18 reverse stock split, reducing shares to ~3.25M

VYNE Therapeutics Inc.

1:18 reverse stock split effective Feb 10, 2023; shares outstanding drop from 58.5M to ~3.25M.
Board approved final ratio on Feb 8; stockholders authorized range 1:10–1:25 at Jan 12 special meeting.
No fractional shares issued; cash payments in lieu. Trading on split-adjusted basis begins Feb 13, 2023.
CUSIP changes to 92941V 308; all stock options and warrants adjusted proportionally with higher exercise price.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

VYNE Therapeutics Inc.: Effected a one-for-eighteen reverse stock split of common stock via Certificate of Amendment to Amended and Restated Certificate of Incorporation (effective 2023-02-10).

Change: charter amendment
Effective: 2023-02-10

Exact text from the filing

On February 10, 2023, VYNE Therapeutics Inc. (the “Company”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”) to effect a one-for-eighteen (1:18) reverse stock split of its outstanding common stock, effective as of February 10, 2023 (the “Reverse Stock Split”).

View on SEC.gov

Browse all governance changes →

VYNE Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-018639

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.